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Abstract 
 
Tuberculosis (TB) is a disease caused by the bacterium Mycobacterium tuberculosis, a 
pathogen that has accompanied mankind throughout its far and recent history. Current TB-
therapy consists of two treatment phases, one initial phase where a cocktail of four frontline 
anti-tubercular drugs are administered daily for a minimum of two months followed by a 
continuation phase where two or more drugs are taken for a minimum of four months. The 
extensiveness of the treatment is a problem as it becomes very costly and hampers patient 
lifestyle. In turn, this may lead to patient non-compliance and an increased probability of the 
emergence of drug resistant strains. There is thus a great need for developing new drugs and 
to improve the efficiency of current drugs. Our group has developed a method for 
encapsulating one of the frontline anti-TB drugs, rifampicin (RIF), in the biodegradable 
polymer Poly-Lactic-co-Glycolic-Acid (PLGA). The idea behind encapsulating the drug is to 
promote its gradual release, increase its residence time in the body, to promote a natural co-
localization between drug and pathogen and by doing so, enhance the therapeutic effect of the 
drug. The main goal of my master project has been to develop and apply methods for 
measuring the effect of these PLGA-RIF-nanoparticles on zebrafish challenged with 
mycobacterial infection. The experiments reveal a decrease in bacterial burden accompanied 
by a significant increase in the survival of zebrafish larvae treated with these nanoparticles 
compared to their free-drug counterparts. This thesis therefore substantiates the claim that 
nanoparticle-based therapy holds real promise for the successful treatment of TB. 
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1 Introduction 
1.1 A brief history of tuberculosis 
Phthisis or consumption, the process in which the substance of a thing is completely 
destroyed, was identified by Hippocrates (460-377 BC) as the most widespread, most lethal 
disease of its time [1]. Findings of tubercular decay in Egyptian mummies dating back to 
3000 BC [2] add further evidence that tuberculosis (TB) has accompanied mankind for a very 
long time. During the 18th and 19th century the disease ravaged Europe and North-America 
earning the nickname “Captain among these men of death,” and it was during this time that 
one began to understand the pathophysiology of the disease [3]. In 1882 Robert Koch 
identified Mycobacterium tuberculosis as the causative agent of TB [4] and about 40 years 
later Albert Calmette and Camille Guérin had developed a vaccine (BCG) by serial passage of 
the closely related species Mycobacterium bovis [5]. From 1952-1961, four new frontline anti 
TB-drugs were introduced, that when used in combination,  has a treatment success rate of up 
to 87% [6]. At present, 11 new vaccines and several new or re-purposed TB-drugs are 
advancing in clinical trials and regulatory review. But despite this continual effort to develop 
tools with which to fight the disease, the World Health Organization (WHO) could in 2012 
report 1.4 million deaths and 8.7 million new cases of TB [6]. Furthermore, it is estimated that 
about one third of the world’s population is latently infected with TB [7]. 
1.2 Initial infection 
Tuberculosis is an airborne disease. A susceptible host may contract the disease by inhaling 
tiny water droplets containing the bacilli that are released when an infected host coughs or 
sneezes [8]. The bacilli need to reach the site of gas exchange, the alveoli, and avoid being 
trapped in the mucosal layers of the upper respiratory tract. Once in the alveoli the bacilli will 
be taken up by professional phagocytes, in particular alveolar macrophages [9] (FIG.1). There 
are many different receptors involved in the uptake of the bacilli, including TLRs, CD14, 
complement receptors, mannose receptor, SPA receptors, scavenger receptors and after the 
onset of adaptive immunity, Fc-receptors [10-16]. It is believed that once having 
phagocytosed the bacilli, the macrophages  infiltrate the subtending epithelial layer causing a 
local inflammation [17]. This inflammation will attract mononuclear cells from surrounding 
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blood vessels, thus providing new host cells for the expanding bacterial population and 
establishing a primary lesion [18].These early lesions form the structural basis for what 
eventually will develop into a tubercle, or granuloma – the hallmark structure of TB [19]. 
Alternatively, the bacilli can be taken up by dendritic cells (DCs) and transported to the 
nearest lymph node for activation of the adaptive immune system [20]. It is believed that 
through the lympho-hematogenous route the bacilli may establish secondary TB-lesions 
throughout the body [21]. This disease state is termed miliary tuberculosis and is particularly 
lethal. The mortality rate of miliary tuberculosis, which most often affects young children and 
HIV/AIDS patients [22], is 30% even when treated [23]. About 80-85% of all cases are 
pulmonary TB wherein the bacilli remain exclusively in the respiratory tissue [24]. 
 
Figure 1: The life cycle of M.tuberculosis. 
The figure shows the process of M.tuberculosis uptake followed by granuloma formation, granuloma caseation 
(accumulation of necrotic cell debris in the centre) and granuloma rupture [25]. 
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1.3 The outcomes of initial infection with 
Mycobacterium tuberculosis 
1.3.1 Primary progressive TB 
Forty percent of infections progress towards primary active TB in which the immune system 
of the host is unable to subvert or contain the bacilli [26] (FIG.2). In this progressive form of 
TB, initial infection is followed by a gradual expansion of infected tissue that could result in 
the complete destruction of the infected  organ [27].  When left untreated, the mortality rate of 
progressive TB is about 66% [6]. 
1.3.2 Latent TB 
In the remaining 60%, TB will persist in a state of latency, a non-transmissible form in which 
clinical signs of disease are absent [28]. It is estimated that one third of the world’s population 
carry this latent version of TB [7]. The majority of this group will live their lives without ever 
knowing that they carry the disease, but some (2-23% lifetime risk) will experience 
reactivation of the infection to secondary active TB. For people with compromised immunity, 
i.e. because of HIV/AIDS or the use of immuno-supressing drugs,  the numbers are much 
higher (5-10% annual risk) [29].  
 
Figure 2: Outcomes associated with exposure to Mycobacterium Tuberculosis [26]. 
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1.4 The granuloma 
In mice, TB-specific lymphocytes can be detected 2-3 weeks post-infection [28]. Their 
appearance mark the onset of a “containment”-state wherein the bacterial burden remains 
relatively constant [30]. T- and B-lymphocytes migrate to and associate with the periphery of 
the developing granulomas. The classic TB granuloma is highly vascularized, with infected 
macrophages in the centre. These are surrounded by other macrophages that differentiate into 
several different morphotypes; epitheloid macrophages, giant multinucleated macrophages 
and foamy, lipid-filled macrophages [25] (FIG.1). Towards the periphery of the granuloma 
one finds fibroblasts, which synthesize a fibrous cuff that encloses the central structures, and 
excludes  the majority of lymphocytes from the core of the granuloma [31].  It was a long 
held view that granuloma formation was purely a host defensive mechanism. By constructing 
a static and impermeable barrier around the foci of bacterial growth, the granulomas were 
believed to thwart and contain the infection [32]. However, studies by Ramakrishnan et.al 
have shown that superinfected mycobacteria rapidly traffic into pre-existing granulomas in 
the zebrafish model, indicating that the granulomas are more dynamic than once believed. 
Another crucial finding was that macrophages, although they are important in curtailing 
bacterial growth, may be unwitting accomplices in the spread of the bacilli during early stages 
of infection [33, 34]. In progressive forms of TB, granuloma centers become less vascularized 
causing hypoxia and caseating necrosis (caseum=cheese, refers to the cheese-like substance 
that consists of liquefied, necrotic cell debris in the granuloma core) [35]. Ultimately the 
granuloma ruptures, spilling thousands of viable bacilli into the airways. This leads to 
coughing and the release of aerosolized bacilli that may infect a new host [36]. A granuloma 
may also rupture into a blood vessel and cause the miliary tuberculosis described 
previously[27]. 
1.5 Why we have failed to eradicate the disease? 
1.5.1 Failure of our own immune system 
Only about thirty percent of those who have been exposed to the TB bacilli will contract the 
disease [26]. So under normal circumstances our immune system is successful in its attempt 
to clear the pathogen. The macrophages will internalize the bacilli and sequentially fuse the 
phagosome with early and late endocytic organelles and become phagolysosomes. The 
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tubercle bacillus however has the ability to arrest phagosomal maturation and prevent 
phagolysosomal fusion [37](FIG.3). It is this ability that is most widely attributed the tubercle 
bacilli’s enhanced survivability inside the macrophage, as it allows them to avoid the 
bactericidal environment of the phagolysosome. M.tuberculosis-containing phagosomes fail 
to acidify [38] and fail to acquire mature lysosomal hydrolases [39], while they retain access 
to recycling endosomes that can provide crucial nutrients, such as iron, to the pathogen [31]. 
Several mechanisms have been implicated in this phagosomal maturation arrest, for instance; 
inhibition of calcium transients prior to phagosome fusion [40], altered lipid and protein 
composition of the phagosome preventing assembly of factors that control fusion events [41, 
42], inhibition of actin assembly by phagosomes [43] and interference with the Rab-
controlled trafficking system [44]. The mechanisms underlying this pathogen survival-
strategy are probably multi-factorial, but they remain poorly understood. Some reports 
suggest that the bacilli can inhibit MHC class II processing and presentation, thereby 
preventing the recognition of infected macrophages by CD4
+
 T cells [45]. Immunoglobulin-
coating of the pathogen and exposing macrophages to interferon gamma (IFNγ) increases the 
chance that the pathogen will be sequestered into phagolysosomes [46, 47], so a competent 
immune system is still critical in fighting the infection even if the pathogen may have evolved 
strategies for evasion. 
 
Figure 3: M.tuberculosis prevents phagosomal maturation 
Shows how phagosomes containing none-pathogenic E.coli mature and fuse with an acidic lysosome resulting in 
the destruction of the bacterium. Phagosomes containing M.tuberculosis (or BCG) are prevented from maturing 
and fusing with the lysosome. As a consequence the pathogen is not destroyed (courtesy of G.Griffiths).  
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1.5.2 Failure of the medical/research community 
One might also ask why we, as a research/medical community, have failed to eradicate the 
disease. The question should be even more imposing when we know that we have a vaccine 
and effective chemotherapeutic agents at our disposal. Some of the problems with the current 
chemotherapy are already highlighted. Problems with chemotherapy-treatment are 
confounded by the fact that the pathogen has a nearly impenetrable cell membrane [48] and 
has the ability to up-regulate efflux pumps that can expel intracellular drugs [49]. The 
emergence of multidrug resistant strains of  the tubercle bacilli (MDR-TB), which accounted 
for 3.7% of all new cases and 20% of all previously treated cases in 2012 [6], should provide 
additional motivation to develop new medicine. In addition, it has proven difficult to develop 
a vaccine that provides lifelong protection against the disease. This is much down to the fact 
that an individual is susceptible to reinfection even after a natural primary infection and 
clearance [50]. The current vaccine, Bacillus Calmette-Guèrin or BCG, seems to be partly 
effective in some parts of the world [51] but not in others [52]. A reason for this discrepancy 
might be attenuation of the vaccine because of serial passages or other preparation methods, 
making the vaccine become too benign to elicit an adaptive immune response [53]. Another 
explanation could be induction of tolerance to BCG after contact with environmental 
mycobacteria [54]. Although development of more effective vaccines is desirable, it is 
important to add that even if we gave to every human being, a vaccine that effectively blocked 
all transmission of the disease we could still expect several hundred millions new cases of 
active TB due to reactivation of latent infections.  
1.6 Introducing nanobead-based interventions for 
treatment of tuberculosis 
Several groups have introduced the interesting concept of using nanoparticles (NPs) in TB 
therapy. The basic idea is to encapsulate anti-tubercular drugs inside a biodegradable 
polymer. When administered to the patient the desired effects are as follows: the gradual 
breakdown of the matrix should lead to gradual release of encapsulated drug, the matrix 
should protect the drug against enzymatic breakdown thus prolonging its residence time in the 
patient and the increased size of the construct should exceed the renal threshold thus avoid 
kidney filtering and again, prolonging residence time. These traits are desirable for many 
drugs aimed at clearing many different infections. There could also be one specific advantage  
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Figure 4: Nanobeads encapsulating drug have longer residence time compared to free drug  
Plasma drug levels following a single oral administration of three frontline anti-TB drugs rifampicin (RIF), 
isoniazid (INH) and pyrazinamide (PZA) to guinea pigs. Results are mean ± SD, n = 5-6 [55]. 
 
Table 1: Therapeutic effect of nanobeads loaded with rifampicin 
The table shows the therapeutic effect of PLGA nanoparticles loaded with rifampicin compared to the same 
amount of free rifampicin in treating guinea-pig infected with M.tuberculosis. Results are based on visible 
growth of M.tuberculosis on 7H10 agar 21 days post-infection. Results show mean ± SD, n = 5-6 [55]. 
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Figure 5: Microscopy of Nanoparticles.  
Images obtained using TEM (A and B), confocal microscopy (C and D) and SEM (E and F). A, C and E show 
NPs made with the standard preparation method while B, D and F show the NPs prepared after selective 
centrifugation [56]. 
 
to encapsulating drugs aimed at clearing granulomatous diseases. Phagocytic cells can ingest 
particles with diameter sizes ranging from 100nm to 10µM [57]. This is an attractive scenario 
since the tubercle bacilli reside mainly in professional phagocytes, namely macrophages. Not 
only do the macrophages harbor the bacilli, but they are actively recruited to the developing 
granulomas, the foci of bacterial growth [17]. A desired effect of treating TB with nanobeads 
is thus a natural co-localization between the drug and the pathogen. Prof.Gopal Khuller and 
his collaborators have pioneered work on nanobead-based interventions for treating TB. In a 
series of papers his group convincingly demonstrates the effects of encapsulated anti-TB 
drugs on gradual release, prolonged residence time and improved therapeutic effect in the 
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mouse and guinea pig models [55, 58-61] (FIG.4 and TABLE.1). In collaboration with the 
Khuller group and polymer chemists from Professor Bo Nystrom’s group at UiO, Federico 
Fenaroli has succeeded in making PLGA nanoparticles encapsulating rifampicin (RIF), one of 
4 frontline anti-TB drugs, of sizes ranging from 50nm to 2µM (FIG.5) and drug loading 
around 34% (w/w). RIF exerts its bactericidal effect by binding to the DNA-dependent RNA-
polymerase thereby blocking transcription [62]. PLGA has been our preferred choice of 
polymer due to its biodegradability and biocompatibility [63]. Other polymers such as 
chitosan [64] and alginate [65] have been explored as alternatives to PLGA, but we have had 
best results using PLGA. These NPs can be administered to mammalian models through the 
oral-, inhalation- or intravenous route [55]. The main focus of my work has been to evaluate 
the effect of these nanoparticles in treating zebrafish larvae challenged with mycobacterial 
infection. 
1.7 Experimental models of TB pathogenesis 
Many discoveries about the pathogenesis of mycobacteria have been made using cultured 
cells [66]. Drosophila and Dictyostelium have been used to elucidate host-pathogen 
interactions during early infection [67, 68], but to understand the complexity of the events 
leading to granuloma formation and disease states, vertebrate models are needed. The animal 
model that most closely recapitulates the progression of human TB is the macaque [69]. 
However due to cost and ethical considerations the use of this model has been limited. Rodent 
models have been instrumental in unveiling facts about the pathogenesis of TB [70]. They do 
however have their own idiosyncrasies that make them less than perfect models for all aspects 
of human TB. Mice, the most commonly used mode of TB, form poorly organized 
macrophage and lymphocyte aggregates that do not caseate [30]. Guinea-pigs are exquisitely 
susceptible to a progressive pulmonary infection [71], while most rabbits are resistant to 
M.tuberculosis [72]. We have been inspired by the group of Lalita Ramakrishnan at the 
University of  Washington (Seattle, USA) and employed the zebrafish as our model organism 
for unveiling novel aspects about nanobead-based therapies of TB [73]. The key advantage 
for our research is that the zebrafish embryos are transparent, allowing us to perform optical 
measurements which would be impossible on other model organisms. 
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1.8 The zebrafish (Danio rerio) as a vertebrate 
model organism to study TB 
From being an aquarium fish that was occasionally studied in the laboratory in the 1960’s 
[74], the zebrafish has risen to prominence and become a complement and an alternative to 
the mouse model for biomedical research. This fish is an excellent laboratory animal for 
several reasons; they are small, robust, inexpensive to maintain and have well-defined 
husbandry standards.  Embryo development is well characterized and the genome is fully 
sequenced [75-78]. Teleost fish have both an innate and adaptive immune system, with 
conserved orthologues of key human and mouse immune genes [79], including a broad range 
of Toll-like receptors (TLRs) and complement factors [80, 81]. Upon mycobacterial infection, 
the zebrafish develops organized, caseating granulomas reminiscent of human TB albeit with 
fewer lymphocytes [82]. The lymphocytes remain functionally important in curtailing 
bacterial growth since rag1-deficient adult zebrafish (that lack T- and B-cells) are hyper-
susceptible to mycobacterial infection, similar to rag1-deficient mice [73, 83]. Precursor 
lymphocytes can be detected just 3 days post- fertilization (DPF) but they are not fully 
functional until 3 weeks later [84]. Macrophages on the other hand, are able to kill non-
pathogenic bacteria just 1 DPF, while the first neutrophils can be detected 2 DPF [79]. This 
means that there is a window of almost 3 weeks in which we can study the exclusive 
contribution of innate immunity to combat bacterial infection. This makes the zebrafish an 
ideal model for investigating the initial events of TB-pathogenesis, from early infection to 
granuloma formation. 
Fertilized zebrafish embryos are kept at 28 ˚C. This is a non-permissive temperature for M. 
tuberculosis growth. We therefore use a close relative of M.tuberculosis, namely 
Mycobacterium marinum, as a model for TB in the zebrafish embryo. 
1.9 Mycobacterium marinum 
Mycobacterium marinum is a macrophage pathogen that causes a systemic, granulomatous 
disease in ectotherms [85]. In contrast to M.tuberculosis, which is transmitted almost 
exclusively from lung to lung, M.marinum inhabits marine and freshwater reservoirs [86]. It 
grows optimally at 25-35 ˚C so manifestation of human infection is primarily limited to the 
extremities [87]. This species of Mycobacterium was originally isolated in Sweden in 1951 
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[88] and phylogenetic studies later revealed its close relation to M.tuberculosis [89] (FIG.6). 
A framework of pathogenesis seems to be conserved between the two species. They both 
survive inside macrophages by arresting phagosomal maturation, they induce similar initial 
host response to infection with elevated expression of TNFα and IL-1β and they both 
extravasate into tissue to form granulomas [90, 91]. The M.marinum genome is 85% identical 
to orthologous regions of the M.tuberculosis genome, and coding sequence amino acid 
identity averages 85% between orthologues. At 6.6Mb the M.marinum genome is about 1.5 
times the size of the M.tuberculosis genome, perhaps reflecting its expanded environmental 
host range [92]. Mutational analyses into the 2.2Mb that is unique to M.marinum and the 
0.6Mb that is unique to M.tuberculosis, have yielded very few virulence phenotypes [93, 94]. 
Furthermore, immunization with M.marinum has been shown to provide protection against 
M.tuberculosis in the mouse model [95].  
 
Figure 6: Phylogenetic tree showing the close genetic relation between M.marinum and M.tuberculosis 
Phylogenetic tree based on the alignment of partial 16S rRNA gene sequences illustrating the positions of strains 
of M.ulcerans, M.marinum, M.tuberculosis and M.haemophilum and other slowly growing mycobacterieal 
species. The tree was rooted by use of N.asteroides as an outgroup. The bar indicates a 10-nucleaotide (10-nt) 
difference [89]. 
 
Prof. Astrid van der Sar of Vrije Universiteit Medical Center, The Netherlands, has proposed 
a division of M.marinum-strains based on genetic diversity and virulence in the adult 
zebrafish; the M-strains which are extremely virulent in the adult zebrafish and most often 
isolated  from human infections, and the E-strains which are less virulent in the adult 
zebrafish and most often isolated from environmental reservoirs [96, 97]. In the beginning of 
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my master thesis project, I wanted to characterize the virulence of this E-strain M.marinum in 
the zebrafish larvae. A less virulent strain of M.marinum could increase the time-frame in 
which we can perform measurements in the young larvae, a seriously limiting factor for some 
experiments. 
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2 Aims  
 
I will show in the Results-section how the M-strain of M.marinum causes a systemic and 
lethal disease in the zebrafish larvae. When untreated, the mortality rates have been around 
60% just ten days post-infection. This has left us with very little time in which to perform 
measurements of the developing infection. As already mentioned, less virulent strains of 
M.marinum have already been used to unveil facts about TB in the adult zebrafish [96, 97].  
 In the beginning of my master thesis project, I therefore sought to evaluate the 
virulence of the E-strain M.marinum (E11) in the zebrafish larvae. The use of this 
presumptive less virulent strain could increase the resolution of our experiments. This 
experiment could also form the basis for studying genetic components of 
mycobacterial virulence. 
When I first started my master thesis, CFU (Colony Forming Units) was the standard method 
for estimating bacterial burden of the zebrafish larvae in our group. Unfortunately there were 
some disadvantages with this method; it has a low throughput, it is labor intensive and since 
the procedure demands that we kill the larvae, huge test groups were required to obtain solid 
statistical data. Furthermore, the results obtained from using this method have proven to be 
unreliable, especially in the early stages of infection when bacterial burden can be low. In 
addition it soon became apparent that the two most prominent groups working on M.marinum 
in zebrafish (Ramakrishnan and Meijer) gave up trying to use CFU analysis and both 
switched to estimating the level of bacterial fluorescence 
 The main goal of my thesis has therefore been to develop and apply a method for 
measuring the therapeutic effect of NP-treatment of tuberculosis in the zebrafish larval 
model. The method is called fluorescent pixel count (FPC) and is made possible by 
infecting the transparent zebrafish embryo with M.marinum that carries a fluorescent 
marker. 
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3 Methods 
3.1 Zebrafish breeding and maintenance 
From Darren Gilmour at EMBL (Heidelberg, Germany), we received ∼100 Nacre -/- strain 
embryos that were grown to adulthood by Jan-Roger Torp in Peter Aleström’s zebrafish 
facility at the Norwegian School of veterinary Science.  The Nacre strain is transparent from 
embryo until adulthood. Some of the adult fish were later transferred to our facility at the UiO 
where they are now kept at 28ºC in well-aerated tanks. Approximately 10% of the tank water 
is replaced every day by fresh system water and the light cycle is 12:12 hrs. The fish are fed 3 
times per day, once with SDS 400 dry food (Lillicotech) and twice with brine shrimp. The 
zebrafish can breed every two weeks. On the day before breeding 3 males and 2 females are 
placed in a tank separated by a splitter. The bottom of the tank is filled with marbles to keep 
the fish from eating the eggs. The zebrafish breed at dawn and so in the morning before the 
light cycle begins, the splitter is removed to allow the males access to the females. Once the 
light cycles has begun the spawning goes on for ∼2 hrs after which we can collect the 
fertilized eggs.  The embryos are transferred to sterile embryo medium (see recipe) and kept 
at 28ºC until they are dechorionated ∼30 hrs post-fertilization. 
3.2 Preparation of PLGA nanoparticles enclosing 
the drug rifampicin 
Adapted from Kalluru 2013 [56]. 
Materials 
PLGA (Poly (D,L)-lactide-co-glycolide) 50:50 RESOMER® RG 502 (Evonik Röhm Gmbh) 
Polyvinyl alcohol (PVA) (Alfa Aesar)  
Rifampicin (RIF) (Sigma-Aldrich) 
Dichloromethane (DCM) (Sigma-Aldrich) 
Coumarin-6 (Aldrich)  
15 
 
Mannitol (Sigma-Aldrich) 
Procedure 
An oil-in-water emulsion (O/W) using the solvent evaporation method was used as our 
standard procedure to prepare rifampicin loaded nanoparticles. Rifampicin (100mg) and 
PLGA (100mg) were dissolved in 10 ml DCM, with or without 0.2 mg of coumarin-6 and 
stirred overnight at room temperature. For the water phase 200 mg of PVA was dissolved in 
20 ml water (prefiltered using a 0.2 μm filter) with heating to 90ºC for 1hr and stirring 
vigorously with a magnetic stirrer overnight at room temperature. The two solutions were 
mixed and tip-sonicated (Sonics, Vibracell) for 3 minutes to obtain the emulsion. 
Subsequently, the emulsion was put in a flask and kept stirring, allowing complete 
evaporation of the DCM within 10-14 hours. For this, a piece of aluminum foil was applied 
on the top of the flask and punctured with a hole of about 0.5 cm diameter. Once the 
evaporation step was completed, NPs were washed twice with water and collected via 
centrifugation at 8000 rpm for 20 min using a Beckman coulter 32 Ti rotor. Subsequently, 
they were re-suspended in a 0.5% mannitol solution, freeze-dried for 2 days and stored at 4ºC. 
3.3 Preparation of M.marinum stocks for infection of 
zebrafish embryos 
Adapted from Cosma et.al 2006 [98]  
Materials 
7H9 liquid culture medium (see appendix - recipes) 
ADC (see appendix - recipes) 
20% (v/v) Tween 80 (Sigma-Aldrich) 
PBS with 2% (w/v) polyvinylpyrrilidone (PVP) (Merck) 
M.marinum frozen stock or bacterial colony of either the M- or the E-strain (see appendix – 
bacterial strains) 
Kanamycin (Sigma-Aldrich) or Hygromycin (Sigma-Aldrich) 
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33˚C incubator 
Procedure 
2mL of ADC and 50µL of 20% (v/v) Tween 80 was added to 18 mL of 7H9 liquid culture 
medium. 16 µL of 50mg/mL kanamycin or 20µL of 50mg/mL hygromycin was added for the 
M- and the E-strain respectively. The medium was subsequently inoculated with a small 
scraping of bacterial colony or M.marinum frozen stock. The flasks were then incubated at 
33ºC until it reached log-phase growth that is an OD600 between 0.3 and 1.2 (may take several 
days depending on you starting bacterial concentration). To measure the OD600, 1.5mL of the 
inoculum was pipetted into a microcentrifuge tube, and spun at maximum speed in a 
microcentrifuge. The supernatant was replaced with 2% PVP in PBS. The solution was then 
passed through a 27g needle repeatedly until it was well dispersed, then loaded into a 
polystyrene cuvette for OD600-measurement. The measurement was performed by using an 
Eppendorf Biophotometer and we confirmed that the OD600 was within log-phase range. 
3.4 Injection of zebrafish embryos with M.marinum, 
PLGA-RIF nanoparticles or free RIF by 
microinjection 
Adapted from Cosma et.al 2006 [98]  
Materials 
M.marinum in log phase growth in 2% (w/v) PVP (Merck) in PBS (see protocol) or PLGA 
nanoparticles in 2% (w/v) PVP in PBS  
Zebrafish embryo medium (see appendix - recipes) 
2% (w/v) phenol red (Sigma-Aldrich) for visualization  
Tricaine stock solution (see appendix – recipes) 
2% (w/v) agarose plates 
Dechorionated zebrafish embryos 48hrs post-fertilization  
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Borosilicate capillaries (SM100F10-Harvard Apparatus) 
Micropipette-puller (Sutter P-97) 
Mineral oil (Sigma-Aldrich) 
Glass slide with a 0.1mm ruler (Leica) 
Micromanipulator (Narishige MN150) 
Microinjector (Eppendorf Femtojet) 
Jeweller’s forceps (Dumont No.5) 
Water bath ultrasonicator (Merck) 
Procedure 
Preparing the needle for injection 
Bacteria were prepared for injection as described in previous protocol and phenol red was 
added to a final concentration of 0.2% (v/v). By using a micropipettor with a microloader tip, 
5 µL bacterial suspension was drawn up to fill the injection needle ( needles were pulled with 
the following settings: Heat=610, Pull=40, Velocity=80, Time=5). The injection needle was 
mounted to the microinjector/micromanipulator and positioned at the microscope where the 
injection would take place. A droplet of mineral oil was added to a glass slide with a 0.1mm-
ruler and placed underneath the needle tip. The tip of the needle was subsequently immersed 
in the oil and broken off with a pair of jeweller’s forceps. The solution was injected into the 
oil and the diameter of the droplet, visible because of the phenol red, was measured against 
the ruler underneath. By using the forceps, enough of the needle tip was broken to obtain a 
droplet of the desired size. The size of the droplet was also regulated by adjusting pressure 
and ejection time on the microinjector. 
Preparing embryos for injection 
A small number (2-10 depending on operator speed) of dechorionated embryos, were 
transferred to a small petri dish with sterile embryo medium and tricaine stock solution 
(300µL tricaine stock solution added to 4.7 mL embryo medium) and left for at least 2 min for 
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full anaesthesia. The embryos were transferred to a 2% agarose plate, excess liquid was 
removed and the embryos positioned so that the needle pointed towards the intended injection 
target. 
Infecting embryos with bacterial suspension 
The fish was penetrated such that the needle tip was positioned inside the intended injection 
target (for different injection targets see figure 6). Injection pressure was applied to drive the 
bacterial suspension into the fish.  
 
Figure 6: Different injections targets 
Injections of phenol red dye into the Duct of Cuvier, hindbrain ventricle and the caudal vein at 48hr post-
fertilization [99]. 
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Injecting embryos with PLGA nanoparticles 
The method is very similar to injection of bacterial suspension. The bacterial suspension was 
replaced by PLGA nanoparticle suspension - which is the desired amount of PLGA 
nanoparticles in 2% PVP in PBS with 0.2% Phenol red. The tube containing the PLGA 
nanoparticle suspension was placed in a water bath ultrasonicator for 5 min before the 
solution was loaded into the injection needle. 
Injecting embryos with free rifampicin 
The drug was solubilized in 5% DMSO in PBS before the solution is loaded into the injection 
needle. It was not possible to solubilize PLGA nanoparticles in DMSO as it would dissolve 
the beads. 
3.5 CFU enumeration from zebrafish larvae 
Adapted from Cosma et.al 2006 [98]. 
Materials 
Zebrafish embryo medium (see  appendix - recipes) supplemented with 20 µg/mL kanamycin 
(Sigma-Aldrich) 
Zebrafish embryo medium (see appendix - recipes) supplemented with 200 µg/mL tricaine 
(Argent Laboratories) 
Infected larvae (see method 3.4) 
Trypsin-EDTA (Sigma-Aldrich) 
PBS 
1% (v/v) Triton X-100 (Sigma-Aldrich) 
7H10 agar (see appendix recipes) plates with antimicrobial agents (see appendix - recipes, 
supplements to 7H10) 
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Procedure 
500 µL sterile zebrafish embryo medium supplemented with 20 µg/mL kanamycin was 
pipetted into 2mL micro-centrifuge tubes. One tube was prepared for each larva to be lysed. 
One infected larva was transferred into each tube. Larvae were allowed to soak for 1 hr at 
room temperature. Most of the embryo medium was removed with a pipette tip while care 
was taken that the larvae remained in the tube. 500 µL of zebrafish embryo medium with 200 
µg/mL tricaine was added, and the tubes were placed on ice for 1hr. The tricaine solution was 
removed and then replaced by 150 µL of 1 x trypsin-EDTA. Samples were then incubated for 
1 hr at 30˚C. The tubes were then vortexed on maximum settings for 2 min and micro-
centrifuged briefly at maximum speed to ensure that all the liquid was returned to the bottom 
of the tube. The tubes were subsequently returned to 30˚C. The samples were then vortexed 
every hour until there were no visible signs of larval debris (∼4-5 hrs). When embryo 
digestion was complete, 30 µL PBS and 20 µL of 1% Triton X-100 was added to each tube 
and vortexed for 2 min Samples were then placed in a water bath ultrasonicator for 10 min 
and micro-centrifuged to consolidate the liquid. The entire volume was then pipetted onto 
7H10 agar plates (with antimicrobial agents) and spread evenly. The plates were incubated at 
33˚C until colonies could be counted (∼4-5 weeks). 
3.6 Determining bacterial burden in zebrafish using 
fluorescent pixel count (FPC) 
 
Materials 
An image processing package (Fiji® [100]) 
2% agarose plates 
Sterile embryo medium (see appendix - recipe) 
Tricaine stock solution (see appendix - recipe) 
Zebrafish larvae infected with M.marinum carrying a DSred fluorescent marker (see method 
3.4) 
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Procedure 
Imaging the larvae 
The larvae were transferred to a small petri dish with embryo medium and tricaine stock 
solution (150 µL tricaine stock solution was added to 4.85 mL embryo medium) and left for at 
least 30sec for adequate anesthesia. The larvae were then transferred to a 2% agarose plate 
and placed under a fluorescence microscope (Leica Fluorescence Stereomicroscope model 
M205 FA, with Leica DFC 365 FX Monochrome Digital Camera and Leica Microsystems 
Type EL6000 external light source). It was decided that the spinal cord just posterior to the 
head region was an appropriate focal point (in the z-plane of the fish) and this was where 
every image was taken. Two images were taken of each fish, one in transmission light- and 
one in the fluorescent light channel. The fish was subsequently transferred to a 48-well plate 
with embryo medium.  
Image processing 
The pictures were processed with the Fiji® image processing package (the following steps are 
described exclusively for Fiji®).  A Rolling ball background subtraction [101] was performed 
on every image, using a rolling ball radius that was at least the size of the largest object that 
was not a part of the background. Since this was not always possible a value was set where 
the aforementioned premise held for the vast majority of the images. This procedure was 
performed with the same rolling ball radius on all images. Next, an objects counter analysis 
[102] was performed. The threshold value was set between the lowest grey value of true 
signal (fluorescent M.marinum-signal) and highest value of background signal. Since this was 
not always possible, a threshold value was set where the aforementioned premise held for the 
vast majority of the images. The program was then set to display surface map and statistics. 
The surfaces were controlled to verify that they actually did represent true signals by 
comparing the objects map to the original transmission- and fluorescence images (the image-
processing is depicted in FIG.7). The statistics were subsequently exported to an Excel 
spreadsheet. From the Excel spreadsheet a value for the sum of integrated densities (Int.Den) 
was determined. This is the fluorescent pixel count (FPC) of a particular zebrafish – the 
numerical value that is a measurement for bacterial burden in the infected zebrafish larva. 
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Figure 7: Images of the infected zebrafish as they are subjected to the FPC procedure. 
Transmission image (a), fluorescence image (b), fluorescence image after rolling ball procedure (c) and surface 
map of objects found after thresholding (d) of a zebrafish larva infected with M.marinum then subjected to the 
FPC procedure. 
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4 Results 
4.1 Establishing M.marinum-infection in the 
zebrafish embryo 
Zebrafish embryos (Nacre -/-) were injected with 1nL M.marinum-solution of an OD600 of 0.9 
into the caudal vein at 2dpf. Embryos were imaged the following day and then every second 
day over a 9-day period. Embryo water was replaced every day. 
 
Figure 8: Images of one zebrafish infected with M.marinum. 
A zebrafish infected with M.marinum 1,3,5,7 and 9 days post-infection (a, b, c, d and e respectively). All images 
are in-vivo merged transmission- and fluorescence images. Image f is a confocal image of a cluster of 
M.marinum inside an infected zebrafish larva. Images a-e were taken with a fluorescence stereomicroscope and 
image f was taken with an upright confocal laser scanning microscope. 
 
Individual or small clusters of bacteria were detectable 1dpi. During the first days of 
infection, the bacteria seemed to colonize the tail rather than the head region. During the later 
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stages of infection, the head region was the one most heavily infected. It is not until 5-7dpi 
that big clusters of bacteria can be seen, presumably residing inside granulomas. Since they 
were not fed, uninfected larvae started to die from starvation around 10dpf. By this time about 
60% of the infected larvae had died from M.marinum-infection. 
4.2 E-strain vs. M-strain  
4.2.1 Survival studies 
Zebrafish embryos (Nacre -/-) were injected with either 1nL M.marinum M-strain solution of 
an OD600 of 0.9 or 1.2 nL M.marinum E-strain solution of an OD600 of 0.75 (= same number 
of bacteria) into the Duct of Cuvier at 2dpf. Embryo water was replaced every second day. 
The mortality rate of larvae infected with either the E- or the M-strain is used as an indication 
of the virulence of these two strains.  
 
Figure 9: Survival of larvae injected with mock, E-strain and M-strain solution, experiment 1. 
Cumulative mortality for larvae injected with PBS (mock), M.marinum E-strain and M.marinum M-strain. n≥23 
for all groups 
The mortalities of both M.marinum-strains compared to mock injection were deemed 
significantly different by a Log rank test. There was no significant difference in mortality 
between the two strains of M.marinum. The mortality of the uninfected group was high, 
possibly indicating that the batch of embryos used for this experiment was not in perfect 
health. Because of this, the experiment was repeated except injecting fewer bacteria (1 nL of 
OD600 of 0.36) of both strains and embryo water was replaced every day instead of every 
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second day. The results were similar - significant difference in mortalities between the mock- 
and the two M.marinum-injected embryos, but no difference between the mortalities of the 
two strains of M.marinum. These result differ from what was expected based on experiments 
performed on adult zebrafish [96, 97]. The M-strain-infected adult zebrafish had a 
significantly higher mortality rate than the E-strain-infected ones, but again, this effect was 
not seen in this zebrafish embryo experiment. 
 
Figure 10: Survival of larvae injected with mock, E-strain and M-strain solution experiment 2. 
Cumulative mortality for embryos injected with PBS (mock), M.marinum E-strain and M.marinum M-strain. 
n≥12 for all groups. 
4.2.2 CFU enumeration of infected larvae 
In addition to survival studies on the E- and the M-strain, a CFU procedure was performed 
(see 3.5). 5 larvae from each of the 3 groups were subjected to the CFU enumeration 
procedure at 2, 5 and 8 days post-infection 
 
Figure 11: CFU-counts of the three groups (Mock-, E-Strain and M-Strain-injected embryos) 
CFU counts in the three groups at three different time-points. Numbers are Mean±SD, n=5 in all groups. 
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In all groups the standard deviation was equal to- or higher than the average, possibly 
reflecting the variability with which individual zebrafish embryos respond to mycobacterial 
challenge. The results also reveal one of the shortcomings of the CFU method. In the 
fluorescence microscope we could clearly see bacteria inside the M- and the E-Strain-infected 
larvae at 2dpi. However, these bacteria could not be detected by the CFU method.  
4.3  Problems of the CFU protocol 
It might be possible to dissect the zebrafish larvae and isolate individual organs, but owing to 
their small size (∼4mm length at 7dpf) we preferred to enumerate CFU from the whole 
animal. It is therefore necessary to prevent the outgrowth of the intestinal bacterial flora that 
might contaminate the growth medium. To counter this problem, a cocktail of 5 antibiotics to 
which the M.marinum is supposed to be naturally resistant (see recipe, supplement to 7H10 
agar plates) was added to the solid medium on which we eventually plated our isolated 
bacteria. By plating diluted M.marinum-culture on these plates we sought to find out to what 
extent the heavy antibiotics pressure affected the growth rate of the bacilli. Bacterial cultures 
of ODs600 0.2, 0.5 and 1.5 were diluted by 10
5
. 100 µL of these suspensions were then plated 
on solid medium containing either no antibiotics, 1 antibiotic (kanamycin) or 5 antibiotics 
(see recipe, supplement to 7H10 agar plates). 9 technical replicas were made of each sample. 
The results (FIG.12) show that the 5 antibiotics needed to prevent bacterial flora 
contamination also inhibit M.marinum growth. In fact, the CFU counts were ∼3.5 times 
lower when using the plates containing 5 antibiotics compared to the plates without 
antibiotics. Furthermore, the colonies on the plates containing 5 antibiotics were visible 
after 31 days compared to only 10 days for the plates with no antibiotics. The 5-
antibiotics cocktail consists of kanamycin to which this particular strain of M.marinum is 
resistant and 4 more antibiotics referred to as PACT (polymixin B sulphate, 
amphotericin B, carbenicillin and trimethoprim). The PACT-cocktail is a standard mix 
that is intended for the cultivation of mycobacterial species from specimens containing 
mixed flora [103]. Although several papers mention that the formulation might to some 
extent reduce the recovery of mycobacteria [104, 105], the extent to which it did so in 
our experiments came as a surprise. The CFU method was adapted from Cosma et.al 
2006 [98] and results using this protocol on zebrafish larvae have been published in 
several prestigious journals [33, 91, 106]. 
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Figure 12: CFU counts of 3 different concentrations of M.marinum plated on 3 different plates 
3 different concentrations of M.marinum were plated on 3 different plates containing different antibiotics. The 
estimates for OD600 1.0 are averages of each of the concentrations. n=9 in all groups (number of replicas) 
 
4.4 Measuring the therapeutic effect of PLGA-
nanoparticles encapsulating rifampicin in treatment 
of M.marinum-infection in the zebrafish larvae 
4.4.1 Bacterial burden by FPC 
Since the CFU procedure seemed unable to reliably quantify bacterial presence during early 
stages of infection and probably underestimated the bacterial burden during the whole period, 
I developed the FPC protocol described in the methods section (3.6). I subsequently applied 
this method to measure the bacterial burden in zebrafish larvae infected with 2nL of 
M.marinum suspension with OD600 1.2 at 2dpf, then treated at 3dpf with 1; free rifampicin 
(12mg/kg tissue =  1xhuman dose) and 2; PLGA-nanoparticles encapsulating rifampicin 
(equal RIF-dose). The control groups were as follows: 1; uninfected larvae 2; infected but not 
treated larvae and 3; infected larvae then treated with empty PLGA-nanoparticles. All the 
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larvae were imaged just prior to drug treatment at 3dpf. The larvae were imaged again after 2, 
4, 6 and 8days. The FPC value obtained from the images taken just prior to treatment at 3dpf 
represent initial bacterial burden (0dpt). Since the larvae displayed huge differences in initial 
response to M.marinum-challenge (FIG 13) it was decided that, when presenting the results, 
each time-point should represent change in bacterial burden from this day0-value. Embryo 
water was replaced every day. 
 
Figure 13: Zebrafish embryos respond differently to M.marinum infection.  
Day0 represents 1 day post-infection. The figure shows that despite being injected with the same amount of 
bacteria, the zebrafish embryos have extremely variable levels of bacterial burden after one day. Each point 
indicates the estimate from individual embryos. 
 
Figure 14: PLGA-RIF nanoparticle treatment of M.marinum-infected larvae results in a steady 
curtailment of bacterial growth. 
Log10 FPC changes from day 0 for each of the 5 groups. Calculated as described in the Appendix. The lines 
represent Mean±SEM, n≥15 for all groups. 
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Bacterial burden of the larvae that are infected, but not treated is unsurprisingly the group that 
shows the most significant increase in fluorescence intensity throughout the surveillance 
period. The decrease in burden from day6-day8 in this group can be explained by the fact that 
9 of the highly infected larvae died during this time-period. These larvae had average ΔLOG10 
FPC values of around 3 at the time-point before they died (=10
3
 increase in bacterial burden 
from day 0). This value can be viewed as the maximum bacterial growth that the larvae can 
sustain without dying. Both the rifampicin beads and the free rifampicin had a significant 
therapeutic effect throughout the surveillance period. The rifampicin beads-treated larvae had 
a lower bacterial burden at 8dpt compared to the free rifampicin-treated larvae, but the 
difference was deemed not significant (p-value = 26%). The same two groups show a biphasic 
growth curve although the phases change at different time-points. The big surprise of the 
experiment is still the effect of empty PLGA-beads which after 2dpt exhibited the same 
therapeutic effect as beads containing RIF. 
4.4.2 Survival studies 
The FPC method should have allowed us to perform a survival study on the same larvae. 
However, we needed to feed the larvae during the surveillance period in order to ensure that 
they died from infection rather than starvation. The SDS100 dry food (Lillicotech) is
 
Figure 15: PLGA-RIF nanoparticle treatment significantly increases survival of M.marinum-infected 
larvae compared to free RIF 
Cumulative mortality for each of the 5 groups of larvae. The experiment reveal a significant increase in survival 
of embryos treated with RIF NPs compared to free RIF. n≥15 for all groups. 
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unfortunately intensely fluorescent in both red and green channels and so we performed a 
survival experiment at a later time using the same 5 groups with exactly the same treatment as 
for the previous experiment. The results revealed a significantly lower mortality in larvae 
treated with PLGA-RIF-NPs than in larvae treated with free RIF.  
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5 Discussion 
As an extension of the pioneering work on NPs done by the Khuller lab, our group has sought 
to provide a mechanistic explanation for why the PLGA-RIF nanoparticles appear to work 
better than conventional drugs in treating TB. We propose a model in which the NPs are taken 
up into the M.marinum-infected zebrafish embryos by macrophages that are attracted to the 
foci of bacterial growth – the granulomas, thereby promoting a natural co-localization 
between drug and pathogen. This in turn leads to the enhanced therapeutic effect of the drug 
that is reproducibly seen in our experiments. In order to investigate the validity of this model 
we have adapted some of the procedures developed by Lalita Ramakrishnans group for the 
zebrafish embryos. This optically transparent model organism allows us to perform 
localization experiments wherein we infect the zebrafish embryos with red fluorescent 
M.marinum and later treat it with green fluorescent NPs. Preliminary experiments we 
performed have quantified the degree of co-localization between NPs and M.marinum–
positive cells to around 80% [Federico Fenaroli, unpublished results]. Since we chose the 
zebrafish as our model organism there was a need at the outset to confirm that the reported 
enhanced therapeutic effect of the NPs seen in mammalian models such as mice and guinea 
pigs could also be obtained in the zebrafish model. For this, the methodology that I perfected 
was crucial.  
5.1 Main findings 
The key finding of this thesis is that NP-treatment decrease the bacterial burden and 
significantly increase the survivability of zebrafish larvae infected with M.marinum relative to 
free-drug treatment. Importantly, the method I developed allows us now to reproducibly 
quantify the bacterial load. 
The biphasic growth curve of bacterial burden in the larvae treated with free RIF was 
expected since the literature already emphasizes how free drug is rapidly degraded/excreted 
from in-vivo systems. The biphasic growth curve of our RIF-NPs came as a surprise since the 
presumed steady release of drug should manifest itself as a stable curtailment of bacterial 
growth. In a recent release-experiment however it was revealed that about 80% of the RIF-
content of the NPs was released within 1 day of exposure to an aqueous environment 
[Federico Fenaroli, unpublished results]. Currently we have no method to see where the RIF 
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is located relative to the PLGA-matrix. It could be that a substantial proportion of the drug is 
located outside rather than inside the NP and that this proportion of drug is rapidly released 
from the nanoparticle construct. Such an explanation would fit well with the biphasic growth 
curve seen in experiment 4.4.1 since the RIF beads initially have the same therapeutic effect 
as free RIF, but after this it has no greater effect than the empty beads. Should this experiment 
be repeated, one group of embryos should be infected then treated with both free-RIF and 
empty beads to see if this group would differ from PLGA-RIF beads. However our NPs do 
not require a sustained release of drug in order to be more effective than free drug. If the NPs 
are taken up by macrophages before it has released all its contents they would still have an 
enhanced localized therapeutic effect. Future experiments should try to unveil the kinetics of 
both NP uptake and RIF-release. 
The experiments also reveal that PLGA alone has a pronounced effect on bacterial growth in 
the infected larvae. Considerable effort has been put into unveiling the immunogenic effects 
of this polymer [107-109]. It was discovered that the polymer can be used as an adjuvant to 
increase the effectiveness of vaccines. And indeed, my results indicate that the PLGA 
enhances the bactericidal activity of immune cells in the zebrafish larvae infected with 
M.marinum. 
5.2 E- vs. the M-strain 
The E- vs. the M-strain-experiments showed no difference in either mortality or bacterial 
burden between larvae infected with the two strains. This was unexpected since a striking 
difference in virulence between the two strains in the adult zebrafish is well-documented [96, 
97]. A likely explanation for these findings is that the reported attenuation of the E-strain 
becomes apparent only in the face of a competent adaptive immune system. Adaptive 
immunity is present in the adult zebrafish, on which previous experiments have been 
performed, but absent in the larvae. Had this experiment indicated the same decrease in 
virulence of the E-strain that has been observed in adult zebrafish, my master thesis could 
have taken a different direction with identification of genes involved in the pathogenicity of 
mycobacteria being a main goal of my studies. Since the use of the E-strain would not 
increase the time-frame in which we could perform measurements on the larvae, we 
abandoned the idea of using the E-strain as our standard strain for zebrafish infection. 
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5.3 Fluorescence pixel count is an improvement to 
the CFU procedure 
The development of a robust and sensitive protocol for measuring bacterial burden in 
zebrafish infected with M.marinum was imperative to this research project. The method is an 
obvious exploitation of our transparent model organism and one that several of our 
collaborators in the zebrafish community have taken advantage of. The FPC is less labor 
intensive, higher throughput and more sensitive to low bacterial burden than the CFU 
protocol. As a result, the FPC has been adopted by several members of our group and can 
now be considered our standard method for measuring bacterial burden. The CFU procedure 
remains applicable as a qualitative test for the effectiveness of different infection/treatment-
regiments. Our FPC-protocol differs slightly, and is in our opinion an improvement from the 
one employed by the two most prominent zebrafish-M.marinum groups, Meijer and 
Ramakrishnan, in that it does not only take into account the number of pixels that have 
fluorescence, but also the intensities of  individual pixels. The FPC method has unveiled that 
there is a huge variability among zebrafish larvae in their ability to cope with mycobacterial 
infection. As a result we have had to increase the size of sample groups when performing 
FPC-experiments in order to obtain statistically significant results. Although the procedure is 
a great improvement to the CFU-protocol, some issues need to be addressed. When presenting 
results as increase in bacterial burden from initial burden it is important that all negative 
controls, non-infected fish, have a bacterial burden of zero at all time-points. Out of 74 
images of larvae in this particular group, one larva had a FPC-value different from zero. This 
represents an indefinite increase from the zero-value it held at the previous time-point, and so 
it had to be omitted from the data-set. Furthermore, in 4 out of ∼350 images taken in the 
whole experiment, the rolling ball subtraction algorithm removed obvious “true” 
fluorescence signal. Since this problem only affected larvae with an enormous bacterial 
load with a ratio of true signal/background signal of several orders of magnitude, a 
rolling ball algorithm was not performed on these larvae. 
5.4 The limitations of our model 
In the introduction I have tried to make a case for the relevancy of our model to human TB. 
Nevertheless, our model has certain limitations and these will be addressed in the following 
section. 
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In a widely cited paper from 2002 [110], Ramakrishnan proposes a model of M.marinum-
zebrafish infection wherein infected macrophages extravasate from the blood and into the 
tissue to form granulomas. Such a model would resemble more the human pulmonary TB 
than miliary TB. The implication of such a process would be that circulating drugs would 
have less access to the expanding bacterial population than they would have if the pathogen 
remained closely associated with the vasculature. In our experiments we have found that the 
M.marinum most often remains near the vasculature (see FIG 8f) where they are easily 
accessible to circulating drugs like RIF. The efficiency with which the free RIF is able to 
suppress bacterial growth may thus be overestimated in our experiments compared to its 
ability suppress bacterial growth in human pulmonary TB.  The natural infection route of 
M.marinum into the zebrafish is certainly not through a borosilicate glass needle and it is 
indeed possible that our intravenous infection protocol affects the localization of bacterial 
growth as the disease progresses, i.e. it leads to an abnormal infection scenario. Our group is 
currently trying to establish alternative infection protocols that will more closely recapitulate 
a natural infection such as intra-peritoneal injection, mimicking the possible uptake of 
M.marinum from the gut, or bath infection, mimicking the possible uptake of M.marinum 
through the skin or the gills. For now, the possibility exists that our model more closely 
resembles the miliary form of human TB. 
In the methods section I describe how we solubilize the free RIF in 5% DMSO prior to 
injection into the embryo (3.4). This was necessary since RIF is only slightly soluble in water. 
In addition to being a solvent that dissolves both polar and nonpolar compounds the DMSO is 
well known for its ability to permeabilize organic tissue [111]. For instance, in medicine it is 
used as a topical analgesic to facilitate the absorption of drugs into tissues. This effect can 
also be seen in the zebrafish embryos [112] and is very likely boosting the effect of free RIF. 
Since DMSO dissolves the PLGA NPs it is not possible to use this solvent for both treatment 
protocols. The fact that we use a solvent that likely enhances the effect of free drug makes us 
even more confident that our NPs have additional therapeutic effect. 
It is also important to add that the drug treatment in these experiments was administered just 
once to zebrafish embryos devoid of adaptive immunity and only one day post-infection. In 
order to cure a human TB patient, even with therapeutic NPs, several doses of treatment 
would be required and this treatment would in most circumstances be administered after the 
onset of the adaptive immune response. 
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5.5 Future of nanoparticle-based therapy 
Nanoparticle-based therapy is still in its infancy, but research, including the findings 
discussed herein, suggests that nano-medicine can help us overcome many of the problems 
that traditional medicine is facing today. Should we try to anticipate what the future brings in 
further development in NP-based treatment, we need to consider three factors.  
The first factor is the type of polymer used for encapsulation. Since PLGA is not water-
soluble there has been great interest in finding alternatives to this polymer in order to avoid 
the use of any solvents during the manufacturing process. Both chitosan and alginate are 
being explored, the latter has already been used by the much-cited Khuller to enclose anti-
tubercular drugs [113]. 
The second factor is the type of molecule to be encapsulated and there are many possibilities 
here. Our group is working towards encapsulating a wide array of agents aimed at TB-
treatment. For instance, encapsulation of DNA encoding bactericidal agents such as anti-
microbial peptides or encapsulation of efflux pump inhibitors that might have synergistic 
effects with current drugs [106]. Because of NPs natural ability to target the foci of 
mycobacterial growth, its application could reduce system toxicity effects compared to free-
drug delivery systems. This could in turn make antibiotics that are currently deemed toxic 
become more attractive for TB therapy. Indeed such compounds have been explored, like 
capreomycin, a second-line anti-TB drug that is used when the frontline drugs fail [114]. 
Work is also in progress with encapsulation of M.tuberculosis antigens in order to improve on 
the current BCG-vaccine.  
The potential advantages of nanobead-based therapy are not limited to granulomatous 
diseases like TB. Lasse Evensen in our group is working towards establishing a model 
wherein he uses NPs to treat cancer in the zebrafish. The zebrafish cancer model is already 
well-established in some labs [115, 116]. It is commonly known that endothelial cells at the 
interface between tumor and vasculature are “leaky” [117] thus providing an exit route for 
intravenously injected molecules such as NPs [118]. This phenomenon is in cancer therapy 
often referred to as the enhanced permeation and retention effect (EPR). This system could, 
like our TB-model, display a “natural” co-localization between the drug and its target. In 
cancer therapy however, we do not want NP uptake by phagocytic cells. Modifying the NP-
surface by adding polyethylene glycol (PEG) reduces their uptake and clearance by cells of 
36 
 
the mononuclear phagocytic system, leading to prolonged residence time and increased 
chance that the NPs localize to the tumor [119]. This brings us to the critical third factor; 
targeting molecules added to the NPs. Since the emergence of antibody-technology, a variety 
of affinity ligands have been conjugated to NPs in order to increase their specificity. 
Antibodies, antibody-fragments, peptides, sugars and small peptides have been successfully 
explored as NP targeting agents [120, 121]. It seems to be a particular advantage of the 
nanoparticles used against TB that they work well in the absence of special targeting 
molecules, a consequence of the fact that the macrophages - the site of M.tuberculosis 
residence, are efficient at taking up many different kinds of particles, via ‘non-specific’ 
receptors such as the scavenger receptors [10]. Nevertheless, as pointed out by Kalluru et al 
[56], the NPs in macrophages do not enter the M.tuberculosis-phagosome and the NPs may be 
more efficient when there are targeting molecules such as mannose which, via the mannose 
receptor may help to target the NPs directly into the M.tuberculosis-phagosome. 
We are convinced that therapeutic NPs will play a future role in alleviating the burden of TB. 
Many actual and potential advantages of NP-treatment were nicely summed up in a review 
from Kamaly et.al 2012, [122], most of which are already described in this thesis: “(1) the 
ability to improve the pharmaceutical and pharmacological properties of drugs, potentially 
without the need to alter drug molecules, (2) enhancement of therapeutic efficacy by targeted 
delivery of drugs in a tissue- or cell-specific manner, (3) delivery of drugs across a range of 
biological barriers including epithelial and endothelial, (4) delivery of drugs to intracellular 
sites of action, (5) the ability to deliver multiple types of therapeutics with potentially 
different physicochemical properties, (6) the ability to deliver a combination of imaging and 
therapeutic agents for real-time monitoring of therapeutic efficacy and, (7) possibilities to 
develop highly differentiated therapeutics protected by a unique set of intellectual properties.”  
5.6 Concluding remarks 
The world looks on track to reach WHOs millennium goal of reducing TB incident rates and 
the Stop TB partnership goal of halving 1990 mortality rates by 2015 [6]. Furthermore, the 
emergence of several new or re-purposed drugs represents progress that is unparalleled in the 
last 40 years. But if the success-stories of the 50’s and 60’s teach us anything, it is that initial 
progress needs to be followed up by a continual renewal of commitment in order to maintain 
control of the disease. The emergence of drug-resistant strains of M.tuberculosis remains to 
37 
 
be effectively dealt with, but new therapeutic breakthroughs, in particular the use of NPs, 
could lead the way forward. 
Despite the positive world-wide trend of decreasing incident rates, several developing 
countries have problems with controlling TB. Combined with increasing immigration to the 
western world, this has resulted in an increase in the number of TB-cases in a developed 
nation like the UK. In 2011, a total of 8963 new cases of TB were reported, 74% of which 
were from patients that were born abroad [123]. The trend that the majority of new TB-cases 
originates from patients that have been born, and likely contracted the disease abroad is seen 
in many western countries [6], and it serves to underscore what will be the final point made in 
this thesis; that failure to control TB anywhere translates into failure to truly control TB 
everywhere. 
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6 Appendix 
6.1 Statistics 
P<0.05 deemed differences significant in all statistical tests. 
All survival experiments were analyzed for significant differences with a Log Rank (Mantel-
Cox) test with Graphpad Prism® version 5 
In the bacterial burden FPC experiment (4.4.1) we looked for differences in bacterial growth 
using the Linear Mixed Effect model (LME) with the statistics software “R”.  To analyze 
differences between groups at single time-points we used a one-way Anova with students 
Newman-Keuls post hoc test in Graphpad Prism ® version 5. 
6.2 Calculations 
Calculating the volume and concentration of RIF, PLGA-RIF NPs and 
PLGA NPs to be injected into the zebrafish embryos  
RIF 
1x human dose of RIF = 12mgRIF/kgTissue 
The zebrafish weighs about 1.2mg so in order to have the same drug/tissue-weight ratio as the 
1x human dose we require 12mgRIF/kgTissue x 1.2x10
-6
kgTissue = 14.4x10
-6
 mg RIF 
We use 1mg RIF in 213µL 5%DMSO solution to get a 4.7mg/mL RIF solution. We need to 
inject 14.4x10
-6
mg / 4.7mg/mL = 3.1nL RIF suspension 
PLGA-RIF NPs 
Since our NPs had a drug loading of 34% (RIF/(RIF+PLGA)) we ∼tripled the concentration 
in order to get the same amount of RIF into the embryo. Instead of using 1mg in 213µL 
suspension as we did with the RIF, we used 1mg PLGA-RIF in 71µL suspension to get a 
14.1mg/mL PLGA-RIF NP solution then injected the same amount = 3.1nL PLGA-RIF 
suspension 
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PLGA NPs 
Our PLGA-RIF NPs had a drug loading of 34%, meaning 66% of the weight was from PLGA. 
We needed to inject a solution of concentration 0.66 x 14.1 mg/mL =9.3mg/mL PLGA 
suspension which was easily done by using 1mg PLGA in (1000/9.3) 108 µL solution. We 
then injected the same amount = 3.1nL PLGA- solution. 
Calculating ΔLog10 FPC values 
The FPC values were Log10-transformed, and for each larva, the difference between each 
day’s measurement and the initial bacterial burden was calculated. The growth of bacterial 
burden over defined intervals was calculated by taking the mean and SEM of the ΔLog10 FPC 
values calculated for individual larvae. All FPC-values of 0 were set to 1 to allow Log10-
transformation. 
6.3 Bacterial strains 
The M-strain DS-Red Mycobacterium marinum  was a personal gift from Nathalie Winter and 
Brigitte Gicquel of Institut Pasteur, Paris – France. 
The E-strain DS-Red Mycobacterium marinum (strain E-11) was a personal gift from 
Annemarie Meijer of the University of Leiden, Leiden – The Netherlands. 
6.4 Recipes 
Deionized, distilled water was used in all recipes and protocol steps 
 
7H9 liquid culture medium 
Adapted from Cosma et.al 2006 [98] 
4.7 g Middlebrook 7H9 broth base (Difco) 
4 ml 50% (v/v) glycerol 
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Dissolve the broth base in water, add glycerol, bring to ﬁnal volume of 900 ml, autoclave. 
Store up to 3 months at room temperature. Before use, add 100 ml ADC stock (see recipe) 
and 2.5 ml of 20% (v/v) Tween 80. Store up to 2 months at 4◦C 
 
7H10 agar plates 
Adapted from Cosma et.al 2006 [98] 
19 g Middlebrook 7H10 base (Difco) 
10 ml 50% (v/v) glycerol 
Dissolve the broth base in water, add glycerol, and bring to ﬁnal volume of 900 ml. 
Autoclave, allow cooling to ∼42◦C. Add 100 ml ADC supplement (see recipe). Pour ∼35, 100 
× 15–mm plates. Store up to 2 months at 4◦C 
 
Supplements to 7H10 agar plates 
Adapted from Cosma et.al 2006 [98] 
40 ml 250 µg/ml amphotericin B stock (Sigma-Aldrich) 
500 µl 50 mg/ml polymixin B sulphate (Sigma-Aldrich) 
400 µl 50 mg/ml trimethoprim (Sigma-Aldrich) 
1 ml 50 mg/ml carbenecillin, disodium salt (Sigma-Aldrich) 
Store amphotericin B, polymixin B, trimethoprim and carbenecillin stocks up to 1 year at 
−20◦C 
Supplements are formulated per liter of 7H10 agar plates. 
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Hanks’ stock solutions 
Adapted from Westerfield 2000 [75]. 
Stock #1: 
8.0 g NaCl 
0.4 g KCl 
100 ml H2O 
Stock #2: 
0.358 g Na2HPO4 anhydrous 
0.60 g KH2PO4 
100 ml H2O 
Stock #4: 
0.72 g CaCl2 
50 ml H2O 
Stock #5: 
1.23 g MgSO4·7H2O 
50 ml H2O 
Stock #6: 
0.35 g NaHCO3 
10 ml H2O 
All of Hanks’ stock solutions should be stored indeﬁnitely at 4◦C. 
 
42 
 
ADC supplement 
Adapted from Cosma et.al 2006 [98] 
Dissolve the following in ∼700 ml  H2O: 
50 g BSA, fraction V (Sigma-Aldrich) 
20 g dextrose 
8.5 g NaCl 
Bring to 1 liter ﬁnal volume. Filter-sterilize using a 0.22-µm ﬁlter. Store up to 6 
months at 4◦C 
 
Tricaine stock solution 
Adapted from Cosma et.al 2006 [98]. 
400 mg tricaine (Argent Laboratories) 
97.9 ml H2O 
∼2.1 ml 1 M Tris·Cl, pH 9  
Adjust pH to ∼7 
Store up to 1 month at 4◦C 
Adapted  
Zebrafish embryo medium 
Adapted from Westerfield 2000 [75]. 
1.0 ml Hanks’ stock solution #1 (see recipe) 
0.1 ml Hanks’ stock solution #2 (see recipe) 
1.0 ml Hanks’ stock solution #4 (see recipe) 
43 
 
95.9 ml H2O 
1.0 ml Hanks’ stock solution #5 (see recipe) 
1.0 ml Hanks’ stock solution #6 (see recipe) 
Use about ten drops 1 M NaOH to pH 7.2. Store indeﬁnitely at 4◦C 
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